Tigenix, S.a.u.

Consejo Superior De Investigaciones Cientificas

Universidad Autónoma De Madrid

Centro De Investigaciones Energeticas, Medioambientales Y Technologicas

Tigenix, Sa

Takeda Pharmaceutical Company Limited

Manuel Angel González De La Peña

Dirk Büscher

María Gema Fernández Miguel

Rosa Ana García Castro

Mariano García Arranz

Damián García Olmo

Mario Delgado Mora

Aitor Beraza Pérez

Juan Bueren Roncero

Rosa Maria Yanez González

Maria Lamana Luzuriaga

Dirk BÜSCHER

The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-γ) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.

Cell populations having immunoregulatory activity, method for isolation and uses

Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. This invention relates to the identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. Specifically, it relates to an adult multipotent cell or a cell population or composition comprising the cell, isolated from non-osteochondral mesenchymal tissue, characterized in that it is positive for the following markers: CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 and CD105 and because it lacks expression of the following markers: CD11b, CD14, CD15, CD16, CD31, CD34, CD45, CD49f, CD102, CD104, CD106 and CD133.

Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue

The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-&#x3b3;) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.

Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae.

Use of adipose tissue-derived stromal stem cells in treating fistula

The present invention relates to the use of a particular type of adipose tissue derived mesenchymal stem cells (AD-MSCs), which exert immunosuppressive properties, in the manufacture of a pharmaceutical composition for the prevention and treatment of the graft-versus-host disease (GVHD) produced after allogeneic hematopoietic stem cell transplantation.

Method of treating graft versus host disease using adipose derived mesenchymal stem cells

Growing community of inventors

Madrid, Spain

Manuel Angel González De La Peña